X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA CIPLA NATCO PHARMA/
CIPLA
 
P/E (TTM) x 16.7 40.6 41.2% View Chart
P/BV x 18.0 3.7 483.2% View Chart
Dividend Yield % 0.6 0.5 139.7%  

Financials

 NATCO PHARMA   CIPLA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
CIPLA
Mar-18
NATCO PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs877663 132.3%   
Low Rs424479 88.4%   
Sales per share (Unadj.) Rs223.4189.0 118.2%  
Earnings per share (Unadj.) Rs31.117.6 176.6%  
Cash flow per share (Unadj.) Rs40.334.0 118.4%  
Dividends per share (Unadj.) Rs5.003.00 166.7%  
Dividend yield (eoy) %0.80.5 146.4%  
Book value per share (Unadj.) Rs219.5176.7 124.2%  
Shares outstanding (eoy) m33.07805.12 4.1%   
Bonus/Rights/Conversions PAESOP-  
Price / Sales ratio x2.93.0 96.3%   
Avg P/E ratio x20.932.5 64.5%  
P/CF ratio (eoy) x16.116.8 96.2%  
Price / Book Value ratio x3.03.2 91.7%  
Dividend payout %16.117.1 94.4%   
Avg Mkt Cap Rs m21,504459,724 4.7%   
No. of employees `000NA23.6 0.0%   
Total wages/salary Rs m1,12826,901 4.2%   
Avg. sales/employee Rs ThNM6,446.1-  
Avg. wages/employee Rs ThNM1,139.4-  
Avg. net profit/employee Rs ThNM600.0-  
INCOME DATA
Net Sales Rs m7,389152,193 4.9%  
Other income Rs m1673,577 4.7%   
Total revenues Rs m7,556155,769 4.9%   
Gross profit Rs m1,79328,264 6.3%  
Depreciation Rs m30413,228 2.3%   
Interest Rs m3661,142 32.1%   
Profit before tax Rs m1,29017,470 7.4%   
Minority Interest Rs m460-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m3092,501 12.3%   
Profit after tax Rs m1,02714,166 7.3%  
Gross profit margin %24.318.6 130.7%  
Effective tax rate %23.914.3 167.2%   
Net profit margin %13.99.3 149.4%  
BALANCE SHEET DATA
Current assets Rs m3,681108,141 3.4%   
Current liabilities Rs m3,12338,322 8.1%   
Net working cap to sales %7.645.9 16.5%  
Current ratio x1.22.8 41.8%  
Inventory Days Days8997 92.2%  
Debtors Days Days5974 78.9%  
Net fixed assets Rs m7,685109,411 7.0%   
Share capital Rs m3311,610 20.5%   
"Free" reserves Rs m6,670140,682 4.7%   
Net worth Rs m7,259142,292 5.1%   
Long term debt Rs m95536,621 2.6%   
Total assets Rs m11,957228,606 5.2%  
Interest coverage x4.516.3 27.8%   
Debt to equity ratio x0.10.3 51.1%  
Sales to assets ratio x0.60.7 92.8%   
Return on assets %11.76.7 174.1%  
Return on equity %14.210.0 142.2%  
Return on capital %20.710.0 208.2%  
Exports to sales %39.432.8 120.1%   
Imports to sales %5.70-   
Exports (fob) Rs m2,90849,883 5.8%   
Imports (cif) Rs m421NA-   
Fx inflow Rs m3,44551,691 6.7%   
Fx outflow Rs m70321,033 3.3%   
Net fx Rs m2,74330,658 8.9%   
CASH FLOW
From Operations Rs m1,44014,628 9.8%  
From Investments Rs m-1,089-8,540 12.8%  
From Financial Activity Rs m-353-3,855 9.1%  
Net Cashflow Rs m-12,431 -0.1%  

Share Holding

Indian Promoters % 52.0 16.0 325.3%  
Foreign collaborators % 1.5 20.8 7.1%  
Indian inst/Mut Fund % 7.8 12.2 64.3%  
FIIs % 16.6 23.7 70.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 26.0 26.2 99.2%  
Shareholders   25,395 161,166 15.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - BIOCON LTD COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS